Stramsen Biotech, a Houston, TX-based plant-based biopharmaceutical company, raised $25M in funding.
The round was led by GEM Global Yield LLC SCS, part of GEM.
The company intends to use the funds to:
- Accelerate global expansion initiatives
- Prepare for prospectus submission and pursue an Initial Public Offering (IPO), consolidating its financial position and market visibility.
- Invest in research and development of 33 new drug candidates.
- Initiate the submission of multiple Investigational New Drug (IND) applications with the Food and Drug Administration (FDA), advancing its pipeline towards clinical trials.
- Establish a distinguished Scientific Advisory Board and expand its team.
Led by CEO and President Scott Villwock, Stramsen Biotech is a biopharmaceutical company developing plant-based medicines for infectious and non-infectious diseases.
FinSMEs
07/04/2025